Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics


Ligand Pharmaceuticals Incorporated (LGND)

Today's Latest Price: $116.01 USD

5.24 (4.73%)

Updated Jun 3 11:06am

Add LGND to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

LGND Stock Summary

  • With a price/sales ratio of 16.17, Ligand Pharmaceuticals Inc has a higher such ratio than 91.98% of stocks in our set.
  • Revenue growth over the past 12 months for Ligand Pharmaceuticals Inc comes in at -53.95%, a number that bests just 3.04% of the US stocks we're tracking.
  • Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 33.96%, greater than the shareholder yield of 92.01% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ligand Pharmaceuticals Inc are KMPH, AKTS, PLUG, LJPC, and NUAN.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.
LGND Daily Price Range
LGND 52-Week Price Range

LGND Stock Price Chart More Charts


LGND Price/Volume Stats

Current price $116.01 52-week high $122.08
Prev. close $110.77 52-week low $57.24
Day low $111.21 Volume 201,226
Day high $117.80 Avg. volume 472,575
50-day MA $93.00 Dividend yield N/A
200-day MA $97.87 Market Cap 1.86B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio


Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.


LGND Latest News Stream


Event/TimeNews Detail
Loading, please wait...

LGND Latest Social Stream


Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Ligand CEO Issues Letter to Captisol Customers

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows:

Yahoo | June 1, 2020

LGND or TECH: Which Is the Better Value Stock Right Now?

LGND vs. TECH: Which Stock Is the Better Value Option?

Yahoo | June 1, 2020

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new program incorporates Icagen’s ion channel technology and expertise and is directed at a specific novel ion channel target relevant to neurodegenerative di

Business Wire | May 29, 2020

Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone payment will consist of $2 million in cash and $1 million in Palvella Series C Preferred Stock. Palvella is a privately-held rare disease biopharmaceutical company focused on develop

Business Wire | May 28, 2020

Palvella Therapeutics Completes $45 Million Series C Financing

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and.

Yahoo | May 28, 2020

Read More 'LGND' Stories Here

LGND Price Returns

1-mo 21.12%
3-mo 8.80%
6-mo 7.42%
1-year 1.00%
3-year 4.03%
5-year 23.32%
YTD 11.24%
2019 -23.15%
2018 -0.90%
2017 34.76%
2016 -6.28%
2015 103.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9144 seconds.